Recent advances in histone deacetylase targeted cancer therapy

被引：47

作者：

Hoshino, Isamu ^{[1
]}

Matsubara, Hisahiro ^{[1
]}

机构：

[1] Chiba Univ, Grad Sch Med, Dept Frontier Surg, Chuo Ku, Chiba 2608670, Japan

来源：

SURGERY TODAY | 2010年 / 40卷 / 09期

关键词：

Histone deacetylase inhibitor; Molecular targeted therapy; Cancer therapy; T-CELL LYMPHOMA; SUBEROYLANILIDE HYDROXAMIC ACID; HUMAN COLON-CANCER; PHASE-I; SOLID TUMORS; DEPSIPEPTIDE FR901228; CYCLIC TETRAPEPTIDE; CHROMATIN STRUCTURE; MEDIATED APOPTOSIS; EXPRESSION PROFILE;

D O I：

10.1007/s00595-010-4300-6

中图分类号：

R61 [外科手术学];

学科分类号：

摘要：

Epigenetic regulators such as histone acetyltransferases (HATs) and histone deacetylases (HDACs) are known to play an important role in gene expression. Of these enzymes, HDACs have been shown to be commonly associated with many types of cancers and to affect cancer development. Consequently, HDACs have been considered as promising targets for cancer therapy. In addition, the inhibition of HDACs by histone deacetylase inhibitors (HDACIs) shifts the balance between the deacetylating activity of HDACs and the acetylating activity of HATs in the regulation of gene expression. Therefore, HDACIs are an exciting new addition in cancer therapies. Numerous HDACIs have been identified and some have recently been used in clinical trials for cancer treatment, although the mechanisms underlying the anticancer effects of HDACIs remain unclear. In this review, we examine the most recent developments in HDACIs and various aspects of HDAC-targeted cancer treatment.

引用

页码：809 / 815

页数：7

共 74 条

[71] Depsipeptide-resistant KU812 cells show reversible P-glycoprotein expression, hyper-acetylated histones, and modulated gene expression profile [J].